The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
Identifieur interne : 001E15 ( PubMed/Corpus ); précédent : 001E14; suivant : 001E16The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
Auteurs : Leora Witkowski ; Catherine Goudie ; Pilar Ramos ; Talia Boshari ; Jean-Sebastien Brunet ; Anthony N. Karnezis ; Michel Longy ; James A. Knost ; Emmanouil Saloustros ; W Glenn Mccluggage ; Colin J R. Stewart ; William P D. Hendricks ; Heather Cunliffe ; David G. Huntsman ; Patricia Pautier ; Douglas A. Levine ; Jeffrey M. Trent ; Andrew Berchuck ; Martin Hasselblatt ; William D. FoulkesSource :
- Gynecologic oncology [ 1095-6859 ] ; 2016.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Carcinoma, Small Cell (genetics), Carcinoma, Small Cell (pathology), Carcinoma, Small Cell (therapy), Child, Cohort Studies, DNA Helicases (genetics), Female, Germ-Line Mutation, Humans, Hypercalcemia (genetics), Hypercalcemia (pathology), Hypercalcemia (therapy), Kaplan-Meier Estimate, Neoplasm Staging, Nuclear Proteins (genetics), Ovarian Neoplasms (genetics), Ovarian Neoplasms (pathology), Ovarian Neoplasms (therapy), Prognosis, Transcription Factors (genetics), Young Adult.
- MESH :
- chemical , genetics : DNA Helicases, Nuclear Proteins, Transcription Factors.
- genetics : Carcinoma, Small Cell, Hypercalcemia, Ovarian Neoplasms.
- pathology : Carcinoma, Small Cell, Hypercalcemia, Ovarian Neoplasms.
- therapy : Carcinoma, Small Cell, Hypercalcemia, Ovarian Neoplasms.
- Adolescent, Adult, Age Factors, Child, Cohort Studies, Female, Germ-Line Mutation, Humans, Kaplan-Meier Estimate, Neoplasm Staging, Prognosis, Young Adult.
Abstract
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive tumor, with long term survival at ~30% in early stage disease. SCCOHT is caused by germline and somatic SMARCA4 mutations, but the effect of the mutation type on patients remains unknown. Furthermore, the rarity of SCCOHT has resulted in varied treatment, with no standardized protocols. We analyzed 293 cases to determine the effect of treatment modalities and SMARCA4 mutations on patient diagnosis and outcome.
DOI: 10.1016/j.ygyno.2016.03.013
PubMed: 26975901
Links to Exploration step
pubmed:26975901Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.</title><author><name sortKey="Witkowski, Leora" sort="Witkowski, Leora" uniqKey="Witkowski L" first="Leora" last="Witkowski">Leora Witkowski</name><affiliation><nlm:affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Goudie, Catherine" sort="Goudie, Catherine" uniqKey="Goudie C" first="Catherine" last="Goudie">Catherine Goudie</name><affiliation><nlm:affiliation>Department of Pediatrics, McGill University, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ramos, Pilar" sort="Ramos, Pilar" uniqKey="Ramos P" first="Pilar" last="Ramos">Pilar Ramos</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Boshari, Talia" sort="Boshari, Talia" uniqKey="Boshari T" first="Talia" last="Boshari">Talia Boshari</name><affiliation><nlm:affiliation>Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Brunet, Jean Sebastien" sort="Brunet, Jean Sebastien" uniqKey="Brunet J" first="Jean-Sebastien" last="Brunet">Jean-Sebastien Brunet</name><affiliation><nlm:affiliation>SSENSE, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Karnezis, Anthony N" sort="Karnezis, Anthony N" uniqKey="Karnezis A" first="Anthony N" last="Karnezis">Anthony N. Karnezis</name><affiliation><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Longy, Michel" sort="Longy, Michel" uniqKey="Longy M" first="Michel" last="Longy">Michel Longy</name><affiliation><nlm:affiliation>Cancer Genetics Unit & INSERM U916, Institut Bergonié, Université de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Knost, James A" sort="Knost, James A" uniqKey="Knost J" first="James A" last="Knost">James A. Knost</name><affiliation><nlm:affiliation>Illinois Cancer Care, Peoria, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saloustros, Emmanouil" sort="Saloustros, Emmanouil" uniqKey="Saloustros E" first="Emmanouil" last="Saloustros">Emmanouil Saloustros</name><affiliation><nlm:affiliation>Hereditary Cancer Clinic, Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Mccluggage, W Glenn" sort="Mccluggage, W Glenn" uniqKey="Mccluggage W" first="W Glenn" last="Mccluggage">W Glenn Mccluggage</name><affiliation><nlm:affiliation>Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Stewart, Colin J R" sort="Stewart, Colin J R" uniqKey="Stewart C" first="Colin J R" last="Stewart">Colin J R. Stewart</name><affiliation><nlm:affiliation>Department of Histopathology, King Edward Memorial Hospital, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hendricks, William P D" sort="Hendricks, William P D" uniqKey="Hendricks W" first="William P D" last="Hendricks">William P D. Hendricks</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cunliffe, Heather" sort="Cunliffe, Heather" uniqKey="Cunliffe H" first="Heather" last="Cunliffe">Heather Cunliffe</name><affiliation><nlm:affiliation>Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.</nlm:affiliation></affiliation></author><author><name sortKey="Huntsman, David G" sort="Huntsman, David G" uniqKey="Huntsman D" first="David G" last="Huntsman">David G. Huntsman</name><affiliation><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation><nlm:affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Levine, Douglas A" sort="Levine, Douglas A" uniqKey="Levine D" first="Douglas A" last="Levine">Douglas A. Levine</name><affiliation><nlm:affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Trent, Jeffrey M" sort="Trent, Jeffrey M" uniqKey="Trent J" first="Jeffrey M" last="Trent">Jeffrey M. Trent</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Berchuck, Andrew" sort="Berchuck, Andrew" uniqKey="Berchuck A" first="Andrew" last="Berchuck">Andrew Berchuck</name><affiliation><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hasselblatt, Martin" sort="Hasselblatt, Martin" uniqKey="Hasselblatt M" first="Martin" last="Hasselblatt">Martin Hasselblatt</name><affiliation><nlm:affiliation>Institute of Neuropathology, University Hospital Münster, Münster, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Foulkes, William D" sort="Foulkes, William D" uniqKey="Foulkes W" first="William D" last="Foulkes">William D. Foulkes</name><affiliation><nlm:affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada; Department of Medical Genetics and Cancer Research Program, Research Institute, McGill University Health Centre, Montreal, QC, Canada. Electronic address: William.foulkes@mcgill.ca.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26975901</idno><idno type="pmid">26975901</idno><idno type="doi">10.1016/j.ygyno.2016.03.013</idno><idno type="wicri:Area/PubMed/Corpus">001E15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.</title><author><name sortKey="Witkowski, Leora" sort="Witkowski, Leora" uniqKey="Witkowski L" first="Leora" last="Witkowski">Leora Witkowski</name><affiliation><nlm:affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Goudie, Catherine" sort="Goudie, Catherine" uniqKey="Goudie C" first="Catherine" last="Goudie">Catherine Goudie</name><affiliation><nlm:affiliation>Department of Pediatrics, McGill University, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ramos, Pilar" sort="Ramos, Pilar" uniqKey="Ramos P" first="Pilar" last="Ramos">Pilar Ramos</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Boshari, Talia" sort="Boshari, Talia" uniqKey="Boshari T" first="Talia" last="Boshari">Talia Boshari</name><affiliation><nlm:affiliation>Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Brunet, Jean Sebastien" sort="Brunet, Jean Sebastien" uniqKey="Brunet J" first="Jean-Sebastien" last="Brunet">Jean-Sebastien Brunet</name><affiliation><nlm:affiliation>SSENSE, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Karnezis, Anthony N" sort="Karnezis, Anthony N" uniqKey="Karnezis A" first="Anthony N" last="Karnezis">Anthony N. Karnezis</name><affiliation><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Longy, Michel" sort="Longy, Michel" uniqKey="Longy M" first="Michel" last="Longy">Michel Longy</name><affiliation><nlm:affiliation>Cancer Genetics Unit & INSERM U916, Institut Bergonié, Université de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Knost, James A" sort="Knost, James A" uniqKey="Knost J" first="James A" last="Knost">James A. Knost</name><affiliation><nlm:affiliation>Illinois Cancer Care, Peoria, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Saloustros, Emmanouil" sort="Saloustros, Emmanouil" uniqKey="Saloustros E" first="Emmanouil" last="Saloustros">Emmanouil Saloustros</name><affiliation><nlm:affiliation>Hereditary Cancer Clinic, Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Mccluggage, W Glenn" sort="Mccluggage, W Glenn" uniqKey="Mccluggage W" first="W Glenn" last="Mccluggage">W Glenn Mccluggage</name><affiliation><nlm:affiliation>Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Stewart, Colin J R" sort="Stewart, Colin J R" uniqKey="Stewart C" first="Colin J R" last="Stewart">Colin J R. Stewart</name><affiliation><nlm:affiliation>Department of Histopathology, King Edward Memorial Hospital, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hendricks, William P D" sort="Hendricks, William P D" uniqKey="Hendricks W" first="William P D" last="Hendricks">William P D. Hendricks</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cunliffe, Heather" sort="Cunliffe, Heather" uniqKey="Cunliffe H" first="Heather" last="Cunliffe">Heather Cunliffe</name><affiliation><nlm:affiliation>Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.</nlm:affiliation></affiliation></author><author><name sortKey="Huntsman, David G" sort="Huntsman, David G" uniqKey="Huntsman D" first="David G" last="Huntsman">David G. Huntsman</name><affiliation><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation><nlm:affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Levine, Douglas A" sort="Levine, Douglas A" uniqKey="Levine D" first="Douglas A" last="Levine">Douglas A. Levine</name><affiliation><nlm:affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Trent, Jeffrey M" sort="Trent, Jeffrey M" uniqKey="Trent J" first="Jeffrey M" last="Trent">Jeffrey M. Trent</name><affiliation><nlm:affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Berchuck, Andrew" sort="Berchuck, Andrew" uniqKey="Berchuck A" first="Andrew" last="Berchuck">Andrew Berchuck</name><affiliation><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hasselblatt, Martin" sort="Hasselblatt, Martin" uniqKey="Hasselblatt M" first="Martin" last="Hasselblatt">Martin Hasselblatt</name><affiliation><nlm:affiliation>Institute of Neuropathology, University Hospital Münster, Münster, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Foulkes, William D" sort="Foulkes, William D" uniqKey="Foulkes W" first="William D" last="Foulkes">William D. Foulkes</name><affiliation><nlm:affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada; Department of Medical Genetics and Cancer Research Program, Research Institute, McGill University Health Centre, Montreal, QC, Canada. Electronic address: William.foulkes@mcgill.ca.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Carcinoma, Small Cell (genetics)</term><term>Carcinoma, Small Cell (pathology)</term><term>Carcinoma, Small Cell (therapy)</term><term>Child</term><term>Cohort Studies</term><term>DNA Helicases (genetics)</term><term>Female</term><term>Germ-Line Mutation</term><term>Humans</term><term>Hypercalcemia (genetics)</term><term>Hypercalcemia (pathology)</term><term>Hypercalcemia (therapy)</term><term>Kaplan-Meier Estimate</term><term>Neoplasm Staging</term><term>Nuclear Proteins (genetics)</term><term>Ovarian Neoplasms (genetics)</term><term>Ovarian Neoplasms (pathology)</term><term>Ovarian Neoplasms (therapy)</term><term>Prognosis</term><term>Transcription Factors (genetics)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA Helicases</term><term>Nuclear Proteins</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Small Cell</term><term>Hypercalcemia</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Small Cell</term><term>Hypercalcemia</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Small Cell</term><term>Hypercalcemia</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Child</term><term>Cohort Studies</term><term>Female</term><term>Germ-Line Mutation</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive tumor, with long term survival at ~30% in early stage disease. SCCOHT is caused by germline and somatic SMARCA4 mutations, but the effect of the mutation type on patients remains unknown. Furthermore, the rarity of SCCOHT has resulted in varied treatment, with no standardized protocols. We analyzed 293 cases to determine the effect of treatment modalities and SMARCA4 mutations on patient diagnosis and outcome.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26975901</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>23</Day></DateCreated><DateCompleted><Year>2017</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Gynecologic oncology</Title><ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation></Journal><ArticleTitle>The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.</ArticleTitle><Pagination><MedlinePgn>454-460</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0090-8258(16)30071-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2016.03.013</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive tumor, with long term survival at ~30% in early stage disease. SCCOHT is caused by germline and somatic SMARCA4 mutations, but the effect of the mutation type on patients remains unknown. Furthermore, the rarity of SCCOHT has resulted in varied treatment, with no standardized protocols. We analyzed 293 cases to determine the effect of treatment modalities and SMARCA4 mutations on patient diagnosis and outcome.</AbstractText><AbstractText Label="METHODS">In 293 SCCOHT patients we collected information on age and stage at diagnosis, treatment modality (surgery, chemotherapy, radiotherapy, and/or high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR)), SMARCA4 mutation origin (germline/somatic), and overall survival. Cox analysis and log-rank tests were performed on 257 cases with available survival data.</AbstractText><AbstractText Label="RESULTS">The strongest prognostic factors were stage at diagnosis (p=2.72e-15) and treatment modality (p=3.87e-13). For FIGO stages II-IV, 5-year survival was 71% for patients who received HDC-aSCR, compared to 25% in patients who received conventional chemotherapy alone following surgery (p=0.002). Patients aged ≥40 had a worse outcome than younger patients (p=0.04). Twenty-six of 60 tested patients carried a germline SMARCA4 mutation, including all patients diagnosed <15years; carriers presented at a younger age than non-carriers (p=0.02).</AbstractText><AbstractText Label="CONCLUSIONS">Stage at diagnosis is the most significant prognostic factor in SCCOHT and consolidation with HDC-aSCR may provide the best opportunity for long-term survival. The large fraction of SMARCA4 germline mutations carriers warrants genetic counseling for all patients.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Witkowski</LastName><ForeName>Leora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goudie</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boshari</LastName><ForeName>Talia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunet</LastName><ForeName>Jean-Sebastien</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>SSENSE, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karnezis</LastName><ForeName>Anthony N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>BC Cancer Agency, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longy</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Genetics Unit & INSERM U916, Institut Bergonié, Université de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knost</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Illinois Cancer Care, Peoria, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saloustros</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hereditary Cancer Clinic, Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCluggage</LastName><ForeName>W Glenn</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Colin J R</ForeName><Initials>CJR</Initials><AffiliationInfo><Affiliation>Department of Histopathology, King Edward Memorial Hospital, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendricks</LastName><ForeName>William P D</ForeName><Initials>WPD</Initials><AffiliationInfo><Affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunliffe</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntsman</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>BC Cancer Agency, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pautier</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trent</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berchuck</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasselblatt</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foulkes</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada; Department of Medical Genetics and Cancer Research Program, Research Institute, McGill University Health Centre, Montreal, QC, Canada. Electronic address: William.foulkes@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA195670</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gynecol Oncol</MedlineTA><NlmUniqueID>0365304</NlmUniqueID><ISSNLinking>0090-8258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C084108">SMARCA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018288" MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018095" MajorTopicYN="N">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006934" MajorTopicYN="N">Hypercalcemia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Chemotherapy</Keyword><Keyword MajorTopicYN="Y">Mutation</Keyword><Keyword MajorTopicYN="Y">Ovarian cancer</Keyword><Keyword MajorTopicYN="Y">SCCOHT</Keyword><Keyword MajorTopicYN="Y">SMARCA4</Keyword><Keyword MajorTopicYN="Y">Stem cell rescue</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26975901</ArticleId><ArticleId IdType="pii">S0090-8258(16)30071-3</ArticleId><ArticleId IdType="doi">10.1016/j.ygyno.2016.03.013</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26975901
|texte= The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26975901" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |